Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the following new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out in the Schedule hereto:
Schedule
Product: Evista
Active Ingredient: Raloxifene hydrochloride 60mg equivalent to 55.7mg raloxifene free base
Dosage Form: Film coated tablet
New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturers: Lilly del Caribe. Inc., Puerto Rico
Lilly SA, Alcobendas, Madrid, Spain
Dated this 19th day of February 2009.
MARK RICHARDS, Acting Deputy Director-General, Sector Accountability and Funding Directorate, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).